Hey guys, sorry about the CRL for Levadex. Unfortunately in our industry it is always a possibility. fortunately Allergan is a very strong company and this will not hurt the stock too much. I'm currently invest in PATH and have been since before the FDA approval of their Migraine patch.. I believe this company and product has immense potential moving forward in 2013. We've been patiently waiting for a partnership or buy out announcement and I believe with Levadex out of the game for 2013 it won't be long now.
This isn't to knock your stock or come and pick up the pieces after a CRL, only to give a heads up to those interested.